CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis Pharmaceuticals Corporation v. Lupin Ltd.

1:12-cv-00595

Overview

Case Number 1:12-cv-00595
Filing Date 2012-05-14
Status Terminated
Termination Date 2012-11-06
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Novartis Pharmaceuticals Corporation Operating Company

Represented By

5 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Scott Familant

Email: scott.familant@bakerbotts.com

Patrick Anthony Walker , III

ADDRESS EXPIRED / UNKNOWN

ADDRESS EXPIRED / UNKNOWN

Jennifer Gordon

Email: jengordon@paulweiss.com

Counter Claimant

Lupin Ltd. Operating Company

Represented By

5 Attorneys Listed

Richard L. Horwitz

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

William R. Zimmerman

Email: bill.zimmerman@knobbe.com

Jonathan E. Bachand

Email: jonathan.bachand@knobbe.com

David Ellis Moore

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Andrea L. Cheek

Email: Andrea.Cheek@knobbe.com

Lupin Pharmaceuticals Inc. Operating Company

Represented By

2 Attorneys Listed

Richard L. Horwitz

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

David Ellis Moore

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 1 proceeding
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): GB πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (1 found):
U.S. Courts: 1
U.S. District Court 2012-05-14
1:12-cv-00596

Novartis Pharmaceuticals Corporation v. Torrent Pharmaceuticals Ltd.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6294197
Solid oral dosage forms of valsartan
Filed: 1997-06-18
Issued: 2001-09-25
Expired (Term Ended)
Expires: 2017-06-18
US8101599
Pharmaceutical composition containing anti-hypertensive agents
Filed: 2008-12-18
Issued: 2012-01-24
Active (2.1 yrs remaining)
Expires: 2028-12-18

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(17 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT - filed against Lupin Ltd., Lupin Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 350.00, receipt number 0311-1073138.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A & B, # (2) Civil Cover Sheet)(rwc) Modified on 5/14/2012 (rwc). (Attachment 2 replaced on 5/14/2012) (rwc).

Entry #1 • 2012-05-14
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (rwc)

Entry #2 • 2012-05-14
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 2/3/10. Date of Expiration of Patent: 12/18/17. (rwc)

Entry #3 • 2012-05-14
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,294,197; 8,101,599. (rwc)

Entry #4 • 2012-05-14
1

Disclosure Statement pursuant to Rule 7.1 filed by Novartis Pharmaceuticals Corporation identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation. (rwc)

Entry #5 • 2012-05-14
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc